Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02620683
Other study ID # 15-1741
Secondary ID CHDEN 29920, D01
Status Completed
Phase N/A
First received December 1, 2015
Last updated December 22, 2017
Start date December 2015
Est. completion date September 2017

Study information

Verified date October 2017
Source University of North Carolina, Chapel Hill
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Anecdotal reports suggest buffering lidocaine with epinephrine just before intraoral injection reduces time of onset, results in a deeper anesthetic effect, without the "sting" with injection from a low pH. Additional data are needed to establish clinical important outcomes such as the peak blood level of lidocaine as compared to the non-buffered drug combination.

Clinical pilot studies are proposed as the start of a series of investigations to support or modify the use of the buffered anesthetic for intraoral procedures.


Description:

Specific Aims:

Compare blood levels at 30min post injection mandibular block with buffered and non- buffered 2% lidocaine with 1/100k epinephrine. Assess outcomes (pain levels during and post-injection, and onset of anesthesia symptoms) after buffered and non-buffered oral administration of 2% lidocaine with 1/100k epinephrine. Assess possible topical anesthetic properties of buffered and non-buffered oral administration of 2% lidocaine with 1/100k epinephrine

Hypotheses:

No difference in peak blood levels exist between buffered and non-buffered intraoral injection of 2% lidocaine with 1/100k epinephrine.

Injection of buffered local anesthetic will produce less discomfort for the subject as compared to the drug with a low pH.

Buffered local anesthetic will not produce a topical anesthetic effect

Study Time Frame: 6 months Month One IRB approvals. Recruit volunteers as subjects. Prepare case-books. Months Two-Three Clinical Study Months Four-Five Analyze Lab, QOL data Month Six Prepare Abstracts, Papers

Methods: Blinded, Randomized Clinical Design Recruit subjects with IRB approved consent at UNC Target enrollment 24 subjects Subjects will serve as their own controls in a cross-over AB/BA study design which is uniform within sequences, uniform within periods, and balanced Sample size justification: Primary interest is estimation of effect size from pilot study. 24 subjects should be sufficient to provide data to assess whether a larger study is warranted and provide estimates for sample size calculation for larger studies. Vital signs recorded: 10 min before, during at 30min intervals and after post-anesthetic clinical signs disappear: targeted lower lip no longer numb. Randomized subjects to be injected alternatively with 4cc of buffered and 4cc non-buffered oral administration of 2% lidocaine with 1/100k epinephrine.

SAS will be used to create randomization schedules:

The randomization will be performed first to type of drug given with a balanced randomization (half subjects buffered; half to non-buffered) An OMS resident, Dr Phero, will administer the drugs in the OMS clinic.

In week One each subject would receive anesthetic to block the inferior alveolar and lingual N; Halstead or Gow-Gates techniques. No Buccal N. block. At least a week later injections would involve the alternate local anesthetic combination.

Venous blood samples would be drawn from the antecubital fossa 30min post oral injection and assayed for blood lidocaine levels Timed Assessment: pre, during injection, and post-anesthetic for Clinical Onset of Anesthesia Signs: subject reported molar area numbness and numb lower lip on ipsilateral injected side. Assessment for pain level on injection; modified Likert-type scale

In addition at each clinic session an assessment of a topical anesthetic effect on contralateral lower lip with 5 drops of the injected drug placed on the clinically dry lower lip mucosa, Outcome yes/no.

Data Collection: UNC OMS clinic Venous blood samples (10cc) will be drawn from the antecubital fossa 30min post oral injection. Timed assessment pre, during injection, and post-anesthetic clinical Signs: molar area anesthesia, incisor area anesthesia, and numb lower lip for topical

Data Collection/Analysis:

Data will be managed by study staff. Data collection forms and questionnaires for clinical data will be developed to use Teleform for direct scanning input into an ACCESS database. Similar forms have been used in previous studies. All databases are stored on a password protected School of Dentistry server with specific group assignment. SAS will be used for database management and statistical analysis. Descriptive statistics are used to verify correct entry through range and logical checks.


Recruitment information / eligibility

Status Completed
Enrollment 23
Est. completion date September 2017
Est. primary completion date August 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 30 Years
Eligibility Inclusion Criteria:

- Age 18-30 years

- ASA I

- Willingness to complete QOL instrument

- Willingness to participate in two sessions

Exclusion Criteria:

- Allergy to lidocaine class of anesthetic drugs

- Local anesthetic drug use in past week

- Current symptoms teeth or oral mucosa

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Lidocaine
See above

Locations

Country Name City State
United States UNC School of Dentistry Chapel Hill North Carolina

Sponsors (2)

Lead Sponsor Collaborator
University of North Carolina, Chapel Hill Dental Foundation of North Carolina, Inc.

Country where clinical trial is conducted

United States, 

References & Publications (1)

Phero JA, Nelson B, Davis B, Dunlop N, Phillips C, Reside G, Tikunov AP, White RP Jr. Buffered Versus Non-Buffered Lidocaine With Epinephrine for Mandibular Nerve Block: Clinical Outcomes. J Oral Maxillofac Surg. 2017 Apr;75(4):688-693. doi: 10.1016/j.jom — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Lidocaine Blood Levels 30 Minutes Post Injection Lidocaine blood levels were obtained 30 minutes post injection micro g/L The difference between injection type- 95% confidence intervals for the difference between injection types was calculated. For the outcome variable, an assessment of treatment difference by subject, calculated as 1% Buffered minus 2% Non-Buffered, was performed using Wilcoxon rank sum tests with Proc NPAR1WAY (SAS v 9.3). Statistical significance was set as P < 0.05 for all outcomes. 30 minutes post injection
Secondary Pain Intensity Scores Patients reported pain level immediately after injection of lidocaine via a Likert type scale where 1 = No Pain and 10 = Worst Pain Imaginable.
For the outcome variable, an assessment of treatment difference by subject, calculated as 1% Buffered minus 2% Non-Buffered was performed.
Immediately after lidocaine injection
Secondary Number of Minutes to Anesthesia Symptoms of Lower Lip Patients were instructed to record the time when they experienced the initial indication of anesthesia signs in the lower lip. This was reported as the number of minutes following nerve block injection.
For the outcome variable, an assessment of treatment difference by subject, calculated as 1% Buffered minus 2% Non-Buffered was performed.
Patient report of anesthesia symptom onset following injection
Secondary Topical Anesthesia Effect Contralateral Lower Lip Investigator will administer 5-6 drops of the lidocaine to the contralateral lower lip and immediately ask if signs of numbness are present on the lip.
Patients reported presence of numbness lower lip-Yes or No
At time of administration
See also
  Status Clinical Trial Phase
Completed NCT03652103 - Efficiency of Erector Spinae Plane Block For Patients Undergoing Percutaneous Nephrolithotomy Phase 4
Completed NCT06355817 - Distraction Techniques in Periocular Anesthesia: Tapping vs Vibration N/A
Not yet recruiting NCT02640183 - EMLA Cream in Hysteroscopy Practice Phase 2
Completed NCT04201678 - Effectiveness of Erector Spinae Block in Kyphoplasty N/A
Active, not recruiting NCT00523289 - Cardiovascular Safety Research: Bupivacaine With Vasoconstrictor Versus Ropivacaine in Brachial Plexus Block Phase 4
Completed NCT04634721 - Transversus Abdominis Plan Block, Ultrasound or Laparoscopic? N/A
Not yet recruiting NCT03312959 - Heavy Bupivacaine in Peribulbar Block Phase 4
Completed NCT03838120 - Determination of Minimum Effective Volume of Local Anesthetic in Patients Undergoing Ultrasound-Guided Infraclavicular Approach for Brachial Plexus Blockade Phase 4
Recruiting NCT05446727 - Quadratus Lumborum Block vs Erector Spinal Block for Post Abdomen Surgery Analgesia N/A
Enrolling by invitation NCT04725695 - Preoperative Viscous Lidocaine for Upper Gastrointestinal Endoscopy Phase 4
Completed NCT03839134 - The Effectiveness of Soft Tissue Vibration in Reducing Pain of Local Anesthesia Injection in Adult Dental Patients N/A
Completed NCT05767749 - Split Face Study of the Duration of Local Anesthetics Phase 4
Terminated NCT03606889 - Quadratus Lumborum Block vs Transversus Abdominis Plane Block for Post-prostatectomy Analgesia N/A
Completed NCT02271867 - Thermal QST for Interscale Block Evaluation Phase 4
Not yet recruiting NCT05954689 - Femoral Artery Block for Reduction of Tourniquet Induced Hypertension N/A
Terminated NCT03846102 - MORphine Use in the Fascia Iliaca Compartment Block With UltraSound Phase 4
Completed NCT02643563 - Analgesic Duration of Long Acting Local Anesthetics for Low Volume Ultrasound-guided Interscalene Brachial Plexus Block N/A
Completed NCT02755532 - Bupivacaine Pharmacokinetics in Ultrasound-guided Axillary Brachial Plexus Block. N/A
Withdrawn NCT04761887 - Cool Pre-operative TAP Blocks Phase 1
Completed NCT01115062 - Comparison of Synera Patch Versus LMX-4 Cream Versus Placebo Patch for Pain Reduction During Venipuncture in Children Phase 2